Baxter raises full-year profit forecast on robust demand for medical devices
Aug 6 (Reuters) -Baxter International BAX.N on Tuesday raised its annual profit expectations and beat Wall Street estimates for second-quarter profit on strong sales of its medical devices, driven by robust demand for medical care among patients.
Shares of the company rose 3% to $35.69 in premarket trading.
Medical device makers have been benefiting from increased demand for non-urgent surgeries such as hip and knee replacements over the past few quarters especially among older adults, who deferred these procedures during the pandemic.
Larger peers Stryker SYK.N and Boston Scientific BSX.N also raised their annual profit expectations last month, driven by demand for their medical and surgical devices.
Baxter now expects full-year adjusted profit between $2.93 and $3.01 per share, compared with its previous view of $2.88 to $2.98 per share. Analysts estimated $2.92 per share, according to LSEG data.
Revenue for the second-quarter ended June 30 came in at $3.81 billion, beating estimates of $3.76 billion.
Baxter's kidney care unit, which sells dialysis products, recorded sales of $1.12 billion for the reported quarter, compared with estimates of $1.14 billion.
The company said on Tuesday that it plans to separate the kidney care unit in late 2024 or early 2025. It had initially announced the spin-off plans last year amid supply-chain challenges and weak demand for dialysis operations.
Private equity firm Carlyle Group is in exclusive talks to acquire the kidney care unit for more than $4 billion, including debt, Reuters reported last month, citing a person familiar with the matter.
On an adjusted basis, the company earned 68 cents per share in the April-to-June quarter, compared with estimates of 66 cents per share.
Reporting by Mariam Sunny in Bengaluru; Editing by Shailesh Kuber
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
